# Study of INCA 0186 in Subjects With Advanced Solid Tumors

> **NCT04989387** · PHASE1 · TERMINATED · sponsor: **Incyte Corporation** · enrollment: 57 (actual)

## Conditions studied

- Advanced Solid Tumors
- Squamous Cell Carcinoma of the Head and Neck (SCCHN)
- Gastrointestinal (GI) Malignancies

## Interventions

- **DRUG:** INCA00186
- **DRUG:** Retifanlimab
- **DRUG:** INCB106385

## Key facts

- **NCT ID:** NCT04989387
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-10-04
- **Primary completion:** 2024-09-19
- **Final completion:** 2024-09-19
- **Target enrollment:** 57 (ACTUAL)
- **Why stopped:** This was a strategic business decision. There were no safety concerns contributing to this decision.
- **Last updated:** 2025-09-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04989387

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04989387, "Study of INCA 0186 in Subjects With Advanced Solid Tumors". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT04989387. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*